31 results about "Respiratory allergy" patented technology

The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and / or postnatal administration of a therapeutically effective amount of LGG.

The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and / or postnatal administration of a therapeutically effective amount of LGG.

The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and / or postnatal administration of a therapeutically effective amount of LGG.

This invention pertains to inhibitors of atrial natriuretic peptide receptor A (NPRA) function, such as small interfering RNA (siRNA), useful for reducing the inflammation associated with many human diseases, such as asthma, respiratory syncytial virus (RSV) infection, and cancers (such as melanoma, lung cancer, and / or ovarian cancer) by interfering with NPRA gene expression or otherwise reducing NPRA function within a subject; and methods for treating a subject suffering from, or at risk of developing, an inflammatory disease, respiratory allergy (such as allergic rhinitis and asthma), viral infection, and / or cancer by administering such NPRA inhibitors to the subject.

A composition comprising specific Lactobacillus helveticus strains is provided for reducing the symptoms of allergies originating from food, respiratory or contact allergens. Preferably the composition reduces symptoms of allergies (secondary prevention) while also able to reduce sensitization (primary prevention).

The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and / or postnatal administration of a therapeutically effective amount of LGG.

The invention belongs to the field of traditional Chinese medicine, and relates to a pharmaceutical composition containing traditional Chinese medicinal active components baicalin, icariin and astragaloside IV for preventing and treating respiratory anaphylactic disease. The invention determines the dose range of the traditional Chinese medicinal active components for inhibiting splenic lymphopoiesis of sensitized mice; and proven by further experiments in vitro, compared with single use of baicalin, icariin and astragaloside IV, the pharmaceutical composition provided by the invention has a stronger effect on inhibiting the splenic lymphopoiesis of sensitized mice, and a stronger effect on regulating Th cell differentiation and transformation of corresponding cell factors into the normalstate. The pharmaceutical composition provided by the invention can be used for further preparing a target organ protecting medicament, and preparing a monomer small compound medicament for improvingthe body immunity and preventing and treating respiratory anaphylactic disease.

A method relates to epigenetic markers and their diagnostic and predictive value for respiratory allergy. The method can include assaying a test sample from the patient for a DNA hypermethylation or hypomethylation of at least GLI2 region, in which hypermethylation or hypomethylation of the gene region in the test sample indicates or predicts a respiratory allergy in the patient.

The invention discloses a double-layer horseradish buccal tablet for resisting respiratory tract allergy and belongs to the technical field of health foods or functional foods. The double-layer horseradish buccal tablet is composed of contents and a soluble shell for covering the contents; the contents are horseradish powder or horseradish powder and auxiliary materials required by a preparation process; the shell contains tamarind powder and menthol as well as the auxiliary materials required by the preparation process. The tamarind powder and the menthol have the effect of promoting salivary secretion; water in saliva provides a condition for an enzymatic reaction of the horseradish powder and involves in action of sinigrin and sinigrin enzyme; by the effects of the saliva of the oral cavity and the enzyme, the horseradish powder passes through plant cell walls and releases allyl isothiocyanate within a short time. Due to the temperature of 36 to 37 DEG C in the oral cavity, the enzymatic reaction process and the release of the allyl isothiocyanate are quickened, and the allyl isothiocyanate gets a relatively high concentration in the oral cavity within a short time, so that the allergy can be relieved in an acute stage of the respiratory tract allergy. The double-layer horseradish buccal tablet has a definite effect on the respiratory tract allergy and is goo in taste, low in production cost, convenient to carry and long in quality guarantee period.